<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873675</url>
  </required_header>
  <id_info>
    <org_study_id>AKIparathormoneCRRTstudy</org_study_id>
    <nct_id>NCT03873675</nct_id>
  </id_info>
  <brief_title>Parathyroid Hormone Kinetics During CRRT</brief_title>
  <official_title>Trends in Parathyroid Hormone Plasma Concentration in Multi-organ Failure Critically Ill Patients Undergoing Regional Citrate Anticoagulation Continuous Renal Replacement Therapies - Prospective Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uniwersytecki Szpital Kliniczny w Opolu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uniwersytecki Szpital Kliniczny w Opolu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the parathyroid hormone serum concentrations and
      kinetics in critically ill patients admitted to the intensive care unit due to multi-organ
      failure and undergoing citrate anticoagulation continuous renal replacement therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The change in parathyroid hormone serum concentration during regional citrate anticoagulation continuous renal replacement therapy (CRRT) in the acute phase of critical illness.</measure>
    <time_frame>96 hours</time_frame>
    <description>The first parathyroid hormone serum level will be measured before the start of CRRT (the zero point) Next measurements will be performed every 12 hours. Minimal number of measurements - 6, maximal - 8 per patient.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Critical Illness</condition>
  <condition>Multi Organ Failure</condition>
  <condition>Renal Failure</condition>
  <condition>Circulatory Failure</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>parathyroid hormone</intervention_name>
    <description>10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples (10-20ml) taken from the arterial catheter every 12 hours
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Multi-organ failure with acute kidney injury critically ill patients admitted to the
        critical care unit undergoing regional citrate anticoagulation continuous renal replacement
        therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure
        is defined as a respiratory, circulatory and renal failure.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute respiratory failure

          -  Acute circulatory failure

          -  acute kidney injury treated with regional citrate anticoagulation continuous renal
             replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF

          -  continuous renal replacement therapy started no later than 48 hours after admission

          -  SOFA score 5 or more

        Exclusion Criteria:

          -  age less than 18 years

          -  acute liver failure

          -  hypercalcemia at admission (total calcium plasma level &gt; 10.6 mg/dL; total ionized
             calcium plasma level &gt; 1.35 mmol/L

          -  parathyroid glands disease

          -  end stage renal disease

          -  therapeutic plasma exchange

          -  extracorporeal membrane oxygenation

          -  unfavorable outcome (death) predicted within 72 hours (as assessed by investigator)

          -  lack of relatives consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tomasz Czarnik, MD PhD</last_name>
    <phone>0048669906333</phone>
    <email>tczarnik@mac.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, Poland.</name>
      <address>
        <city>Wroc≈Çaw</city>
        <state>Lower Silesia</state>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marek Bolanowski, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology, Szpital Wojewodzki w Opolu</name>
      <address>
        <city>Opole</city>
        <state>Silesia</state>
        <zip>45-372</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aneta Czarnik, MD</last_name>
      <phone>0048600210054</phone>
      <email>anetaczarnik@icloud.com</email>
    </contact>
    <investigator>
      <last_name>Aneta Czarnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care, Uniwersytecki Szpital Kliniczny w Opolu</name>
      <address>
        <city>Opole</city>
        <state>Silesia</state>
        <zip>45-401</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Czarnik, MD PhD</last_name>
      <phone>0048669906333</phone>
      <email>tczarnik@mac.com</email>
    </contact>
    <investigator>
      <last_name>Tomasz Czarnik, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryszard Gawda, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>May 11, 2019</last_update_submitted>
  <last_update_submitted_qc>May 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uniwersytecki Szpital Kliniczny w Opolu</investigator_affiliation>
    <investigator_full_name>Tomasz Czarnik, MD PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <keyword>parathyroid hormone</keyword>
  <keyword>continuous renal replacement therapy</keyword>
  <keyword>citrate anticoagulation</keyword>
  <keyword>intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

